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Results: Mitogen-activated protein kinase 13 (MAPK13) overexpression was observed in all our
tumour specimens. Subgroup analysis showed that MAPK 13 overexpression correlated with shorter
survival time, and survival gradually worsened with increasing MAPK13 scores. MAPK13
overexpression was found to correlate with tumour stage. 
Conclusion: MAPK13 overexpression is a reliable prognostic marker for human cholangiocarcinoma
and represents a potential target for targeted therapeutic interventions. 
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Background: Hepatocellular carcinoma (HCC) is a major malignancy worldwide. The disease is often
diagnosed at late stage and frequently associated with metastasis, when only limited options are
then available for effective therapies. Phosphatase and Tensin Homolog (PTEN) is a tumor suppressor
implicated in various cancers. However, there are relatively few reports delineating the role of PTEN
in HCC development. 
Objectives: This study aimed to characterize the role of PTEN in HCC. 
Methods: We analyzed the expression of PTEN in human HCCs and correlated it with
clinicopathological findings and patients’ survivals. We also studied the cell migration and invasion
abilities and metalloproteinases (MMPs) in HCC cells and PTEN-null mouse embryonic fibroblasts
(MEFs) in relation to PTEN. 
Results: In human HCCs, we found frequent (46%, N=41) underexpression of PTEN in the tumors
as compared with their corresponding nontumorous livers. In addition, PTEN underexpression was
significantly associated with larger tumor size (p = 0.024) and presence of tumor microsatellite
formation (p = 0.021), the latter being a feature of intrahepatic metastasis in HCC. Significantly, it
was also associated with shorter overall survival of patients (p = 0.021). Stable knockdown of PTEN
in SMMC7721 and BEL7402 HCC cells showed significant enhancement of cell migration and
invasion, as demonstrated with transwell and Matrigel invasion assays, respectively, giving relevance
of PTEN in HCC metastasis. We established PTEN stable knockdown HCC clones and PTEN-null
MEFs. We found marked upregulation (by 3.5 - 10 folds) of MMP2 in these cell models. Furthermore,
enzymatic cleavage of MMP2 was observed in the PTEN-null MEFs as demonstrated by gelatin
zymography. Transient knockdown of PTEN resulted in activation of the NF-\kappaB promoter activity.
Furthermore, the PTEN-null MEFs had upregulation of NF-\kappaB protein level. With bioinformatics
analysis, we found two putative NF-\kappaB binding motifs on MMP2 promoter. 
Conclusion: Taken together, our data showed that PTEN was underexpressed in our human HCCs and
its underexpression was associated with more aggressive tumor behavior. Our findings also suggested
that PTEN suppressed cell migration and invasion by downregulating NF-\kappaB signaling pathway. 
(This study was supported by a Hong Kong Research Grants Council Central Allocation Grant HKU
1/06C and a Hong Kong RGC grant HKU 7436/04M) 
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Background: Mutations in hepatitis B virus (HBV) are known to be related with development of
hepatocelluar carcinoma (HCC). To date, however, association of mutations has been investigated
mainly with single mutation. 
Objectives: The aim of this study was to compare the frequency of knwon mutations of HBV in
combination to analyze the association between HCC. 
Methods: In this study, 135 patients with HBV-related HCC (HCC group) were compared with 135
patients with HBV but without HCC (non-HCC group), who were matched for age, sex and HBeAg
status, and the pattern of mutations were analyzed. Amplication and direct sequencing of the pre-S,
basal core promoter (BCP), and precore (PC) region was performed using nested PCR with specific
primers after extraction of HBV DNA from serum. 
Results: The baseline characteristics between HCC group and non-HCC group, respectively, were as
follows: mean age (44.3±7.8 vs. 44.3±8.0 yrs, matched), proportion of male sex (83 vs. 83%,
matched), HBeAg positivity (71.9 vs. 71.9%, matched), and mean HBV DNA (3.70±3.42 vs. 3.45±3.81
log10 copies/ml, p=0.593). In the HCC and non-HCC group, respectively, there were 25 (18.5%) vs.
6 (4.4%) patients with pre-S deletion mutants (p=0.001, OR=4.649, 95% CI=1.834-11.781), 82
(60.7%) vs 30 (22.2%) patients with BCP mutants (p<0.001, OR=5.415, 95% CI=3.178-9.226), and
35 (25.9%) vs. 34 (25.2%) patients with precore mutants (p=0.889). When comparisons were made
between patients with combined mutations, odds ratio was highest in patients with both pre-S deletion
and BCP mutants (16 (11.8%) vs. 2 (1.5%), p<0.001, OR=8.941, 95% CI=2.014-39.698). 
Conclusion: Our data demonstrate that HCC was associated with pre-S and BCP mutation, and
combination of both mutation had a stronger association compared with single mutation. 
References: Chen BF, et al. High prevalence and mapping of pre-S deletion in hepatitis B virus
carriers with progressive liver diseases. Gastroenterology. 2006;130:1153-68. 
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Background: Among several factors implicated in hepatocarcinogenesis, recent reports highlight
JNK activation and the phosphorylation of Smad3 as key steps in progression of HCC. In particular,
Smad3 is converted into 2 distinctive phospho-isoforms: C-terminally phosphorylated Smad3
(pSmad3C) and linker-phosphorylated Smad3 (pSmad3L). Previous studies suggested that TGF- eta
type I receptor (T etaRI)/pSmad3C pathway inhibits growth of epitherial cells including hepatocytes,
whereas JNK/pSmad3L-mediated signaling promotes hepatic fibro-carcinogenesis in HCV-related
chronic liver disorders. 
Objectives: The aim of this study is to elucidate the role of JNK/pSmad3L and to evaluate the effect
of JNK inhibition on both rat HCC carcinogenesis and human HCC cells. 
Methods: (1) Chemical-induced rat HCC. Male Wistar rats were fed with 100ppm diethylnitrosamine
(DEN) in drinking water for 8 weeks and kept for an additional 4 weeks without DEN. One week after
DEN administration, rats were randomly assigned to either JNK inhibitor (SP600125) group or vehicle
control group. Rats received subcutaneous injections 11 times weekly and were sacrificed for evaluation
of HCC development one week after the last injection. (2) Human HCC cell line. Huh7 cells were infected
with adenoviral vectors encoding dominant negative JNK1 (Ad-dnJNK1) and green fluorescent protein
(Ad-GFP) as a control. Proliferation of cells was quantified 2 days after the Ad-dnJNK1 or Ad-GFP
infection using cell counting kit (CCK) assay. (3) Human HCC samples. Phosphorylation of c-Jun was
evaluated with Western blotting in both non-HCC and HCC tissue samples. 
Results: (1) C-Jun was phosphorylated even 7 days after DEN administration, which was suppressed
by single administration of SP600125. The number of tumor nodules greater than 3mm in diameter
was significantly lower in JNK inhibitor group than that in vehicle control group (7.9±3.1 vs. 18.0±3.5
; p<0.001). The liver weight/body weight ratio was significantly lower in JNK inhibitor group than in
vehicle control group (6.3±1.2 vs. 7.1±0.7 ; p<0.05). Body weight and serum ALT were not different
between the two groups. DEN induced pSmad3L expression and suppresed pSmad3C expression in
non-HCC and HCC tissue as the tumors were enlarged and progressed. Although there were no
differences in pSmad3C expression between two groups, SP600125 suppressed phosphorylation of
Smad3L and c-Myc expression through down-regulation of phosphorylated c-Jun. JNK inhibition
significantly prolonged median survival time in JNK inhibitor group (105 vs. 89 days; p<0.05). (2)
Inhibition of JNK activation by Ad-dnJnk1 significantly attenuated the proliferation of cultured Huh7 cells
(p<0.05). (3) C-Jun was clearly phosphorylated in human non-HCC tissue with HCV than in non-HCC
tissue with HBV. Furthermore, c-jun phosphorylation was enhanced in both HBV and HCV related HCCs. 
Conclusion: Inhibition of the JNK/pSmad3L pathway with SP600125 suppressed the progression
of both rat HCC progression and human HCC cells. Thus, JNK targeting might be a promising
approach in HCC treatment. 
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